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There is increasing evidence that health
and development in adult life is influ-
enced or ‘‘programmed’’ by factors,
including nutrition, operating during foe-
tal life and infancy. Early nutrition in a
variety of animal species, including pri-
mates, has been demonstrated to influ-
ence later outcomes, including the
likelihood of cardiovascular disease, learn-
ing and behaviour problems and longevity
(see supplementary data).
Evidence of programming in humans
has, until recently, come largely from
historical observational studies that
showed associations between small size
in early life and adult disease risk (see
supplementary data). These cohorts were
constructed from available health records.
They by necessity relied on indirect
measures of maternal and infant nutrition
and often lacked detailed data on poten-
tial confounding variables. Many cohorts
enrolled people who were born in the first
half of the 20th century, and it is possible
that the nature and size of any associa-
tions are different in contemporary popu-
lations. Thus, although these studies have
generated considerable interest they have
been unable to examine direct associa-
tions with diet or establish whether
associations are causal and cannot, there-
fore, be used to inform infant feeding
recommendations. This has led to a
greater emphasis on the need for RCTs
to test early nutritional interventions and
prospective observational cohorts.
RCTs are generally accepted as metho-
dologically the best approach for inform-
ing health policy. They can equalise
unknown as well as known confounding
factors and so can demonstrate causation;
they permit estimation of effect size and
so can be used to assess likely economic
benefits; and they can, if adequately
powered, measure expected adverse
effects and thus address safety.
Nevertheless, in the context of nutritional
programming of disease later in life, they
have certain limitations. For example,
some trials cannot be performed because
they would be unethical (eg, breast
feeding versus formula feeding). In addi-
tion, although certain measures during
childhood or adolescence are predictive of
final adult outcome (eg, cognitive func-
tion), other diseases will not become
apparent for decades, necessitating the
use of ‘‘proxies’’ of later disease risk that
can be measured at younger ages.
Contemporary prospective observa-
tional studies are also recognised to be
important in investigating nutritional
programming in humans and are comple-
mentary to RCTs. They identify defined
(often large) populations, measure them
precisely and follow them up longitudin-
ally. If the studies are population based
they might also be more generalisable.
They have better measures of exposure
and confounding factors than historical
cohort studies, and, of particular relevance
to programming research, they may
include detailed early physiological, biolo-
gical and social data, allowing more
complete adjustment for confounding
factors.
Given the obvious requirement for
long-term follow-up in the investigation
of nutritional programming of health
outcomes, an important issue has become
increasingly apparent, affecting both
RCTs and prospective observational stu-
dies, namely, cohort attrition or loss to
follow-up. This is an important issue for
the field, with implications for study
design and funding. The aim of this paper
is to consider the statistical implications
of attrition in both RCTs and cohort
studies to identify the most effective
ways of dealing with attrition when
analysing and reporting studies. Factors
influencing follow-up rates, measures that
can be taken to minimise attrition in
future studies and potential alternative
approaches to the problem are discussed
in the appendices. The paper uses exam-
ples from studies examining the effects of
nutritional interventions or early-life
nutrition on later outcomes, but many
of the conclusions are applicable to
studies in other fields.
WHAT IS AN ‘‘ACCEPTABLE’’ FOLLOW-UP
RATE?
There are no universally agreed criteria for
acceptable follow-up rates in nutritional
RCTs or cohort studies. In RCTs, typi-
cally investigating drugs or other thera-
pies, it has been suggested that a loss to
follow-up (5% is usually of little con-
cern, whereas a loss of >20% poses
serious threats to validity, with in-
between rates leading to intermediate
levels of problems.1 Indeed, a cut-off of
80% is used in Evidence-Based Medicine
(EBM) ‘‘Levels of Evidence’’ to separate
‘‘high’’- and ‘‘low’’-quality randomised
trials.2 This figure is based on the concept
of being able to detect a hypothesised
difference between randomised groups at
follow-up after applying the ‘‘worst case
scenario’’ for missing data – that is,
assuming that subjects lost to follow-up
from each arm of the study have the
outcome seen in the other limb. Although
this approach can easily be applied to
studies with dichotomous outcome mea-
sures (such as death or survival), its
applicability to continuous physiological
variables, such as blood pressure, fat mass
or skin-fold thicknesses, commonly used
as outcomes in nutritional programming
studies is uncertain. Rates of 50–80%
follow-up have been suggested as accep-
table by different authors in the context
of epidemiological cohorts, although in
most cases the validity of these recom-
mendations has not been tested.3 4
WHAT INFLUENCES FOLLOW-UP RATES?
Our own RCTs of infant nutritional
interventions have generally achieved
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high short-term follow-up rates, typically
80–90% at 18 months,5–8 which is in the
range that would be considered ‘‘accepta-
ble’’ for the purposes of EBM. However,
longer-term follow-up rates in our studies
and those reported from other groups
working on the programming of adult
diseases clearly depend on a number of
factors including the age of the subject,
nature and perceived benefit of the test,
degree of inconvenience involved and the
ability to trace and contact subjects.
These points are illustrated in figs 1A
and 1B, which show follow-up rates
attained in different cohort studies and
RCTs according to the age at follow-up
and the nature of the tests used. Further
examples are provided in Appendix 1 in
the supplementary data.
WHAT ARE THE STATISTICAL
CONSEQUENCES OF ATTRITION?
Although we acknowledge the impor-
tance of aiming for maximum follow-up
in any study, in practice it is inevitable
that losses to follow-up will occur, and
these are likely to increase with time.
Given this reality, and assuming that
obtaining follow-up data from RCTs and
cohorts in the field of nutritional pro-
gramming is considered to be worthwhile,
we suggest that, rather than setting a
fixed level of what constitutes ‘‘accepta-
ble’’ follow-up, it is more helpful to
consider the statistical implications of
loss to follow-up and ways in which these
issues can be most clearly presented and
discussed in publications.
Altman9 suggested that ‘‘assessing
whether a trial was a good one should
take account of circumstances, including
what is achievable. In trials of lifestyle
interventions, for example, such as dieting
or smoking cessation, such drop-out rates
(ie, ,20%) are rarely achieved, unless
using an unrealistically short follow-up
period’’. The latter consideration clearly
applies to work in the field of nutritional
programming. Altman further suggests
that ‘‘while there is potential value in
guidelines, these should not in general be
interpreted as rules, and we should not
disguise the fact that exercising judge-
ment is a major element of statistics’’.
Attrition is important statistically for
three principal reasons – its effect on
study power, bias and generalisability:
1. Study power: Reduced sample size
can affect the power of the study to
detect a hypothesised difference. Indeed,
it might be possible from the data
presented in fig 1 to predict whether the
likely sample size available for a follow-up
study will be adequate to detect the
hypothesised difference in outcome. If
there is not a reasonable expectation of
attaining the required sample size, it is
questionable whether it is ethical to
proceed with the study; although in some
circumstances follow-up of an underpow-
ered trial might be justified if data is to be
pooled with those from similar studies
using standardised protocols. We would
argue that loss of sample size may not
always present a serious problem for the
physiological outcomes typically used in
nutritional programming studies (eg,
blood pressure or plasma lipid concentra-
tions), where fairly large effect sizes are
anticipated, requiring generally modest
samples. For example, observed differ-
ences in cardiovascular risk factors
between groups randomised to different
infant diets are typically in the range
0.5–0.7SD, requiring a sample size of
approximately 64–100 per group to
achieve 80% power at 5% significance.10–13
Nevertheless, it is important that, where
possible, trial sizes are large enough to
exclude smaller effect sizes that might
also have public health significance. It is
also important to appreciate that,
although studies should clearly be ade-
quately powered at initiation, including
an allowance for attrition, some out-
comes now being examined at long-term
follow-up in programming research are
not necessarily those for which the
study was initially powered, as the focus
of scientific interest may have shifted
with developments in the intervening
years.
2. Bias can be defined as any systematic
error in a study that results in an incorrect
estimation of the association between
exposure and outcome. Attrition intro-
duces a form of selection bias, since loss to
follow-up is rarely a truly random event.
Dumville et al14 considered the issue of
reporting attrition in RCTs and argued
that researchers should be more explicit
about loss to follow-up and present tables
of baseline data separately for those seen
or not seen. If baseline characteristics are
found to differ between those seen and
not seen at follow-up, or if a potentially
important predictor variable is more
unbalanced between randomised groups
at follow-up than at baseline, this may
suggest bias. Such factors could be
included as covariates in the analyses.
However, although important, this may
still be inadequate since imbalance of
measured characteristics often implies
imbalance of unmeasured characteristics.
Kristman et al3 addressed the statistical
effects of attrition in cohort studies using a
simulation study. They found no impor-
tant bias even with losses of up 60% when
data were ‘‘missing completely at random’’
or ‘‘missing at random’’. The ‘‘missing at
random’’ category assumed that dropouts
were related to a characteristic measured at
baseline or at subsequent follow-up (for
example, socioeconomic status) but not to
the outcome variable being measured. Since
relevant baseline characteristics can be
incorporated as covariates in analyses, this
type of missing data would be considered
to be ‘‘ignorable’’. By contrast, the simula-
tion suggested that when data were ‘‘not
missing at random’’ (that is, dropouts were
related to unobserved information or to the
outcome variable), even small losses to
follow-up (as little as 20%) could result in
considerable bias in the results. In practice,
it is, of course, impossible to identify when
Figure 1 Follow-up rates in selected cohort studies, according to age at follow-up and type of
investigations performed (see below for key). (A) Cohort studies. (B) RCTs. Key to studies a = W12,
b = W13, c = W14, d = W15, e = W16, f = W17,g = W18, h = W19, i = W20, j = W21, k = 13,
l = 17, m = W22, n = W23, o = 18, p = W24, q = W25, r = Fewtrell, unpublished, s = 5, t = 6,
u = 7, v = 16, w = 8 (see supplementary data).
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loss to follow-up is related to unmeasured
variables.
3. Generalisability can be defined as the
extent to which research findings can be
applied to settings other than the study
sample in which they were tested. It is
important to recognise that generalisabil-
ity is an issue in many trials with
excellent follow-up rates and a low risk
of bias. For example, trials in the field of
cardiovascular disease are often conducted
in males, excluding the extremes of age,
and their generalisability to the whole
population and to real-life clinical settings
might be questioned.
In practical terms, attrition may affect
the generalisability of the results to the
wider population either by introducing
bias, which affects the ability to draw the
correct conclusion in the study population
and hence the general population. Even in
the absence of bias, however, attrition can
result in loss of power to a degree that
affects the ability to draw a robust
conclusion in the study population, which
in turn affects generalisability. The rele-
vance of attrition to generalisability is
arguably a greater problem in cohort
studies than in RCTs since the former
are generally designed to be representative
of a particular population. The effect of
non-representative population sampling
in a RCT testing for large physiological
effects in an already selected group of
subjects is perhaps less of an issue. The
decreasing initial participation rates seen
in large cohort studies over the past two
decades, combined with subsequent attri-
tion may pose a further threat to gen-
eralisability, although non-participation
resulted in minimal bias in estimates of
relative risk in one large cohort.15
Attrition and effect size
It is important to consider whether the
observed effect size might itself be influ-
enced by attrition. Using data from the
limited number of studies in fig 1B, we
found no evidence that standardised
effect sizes were greater in studies with
higher attrition rates. It should be noted
that this analysis is itself potentially
flawed since (i) it involves comparing
standardised effect sizes for different out-
comes (sometimes studies find a large
effect size for one outcome combined
with a small effect size for another); (ii)
it is possible that the effect size for certain
outcomes genuinely amplifies with time,
so any apparent relationship between
attrition rate and effect size may not be
causal; (iii) it is possible that studies with
high attrition rates and a large effect size
are more likely to be published than
those with small effect sizes. This analysis
is necessarily limited given the small
number of publications reporting long-
term follow-up of RCTs in the program-
ming field. More comprehensive consid-
eration, however, of the influence of
study characteristics on treatment effects
has been conducted and could be used as a
basis for practice in future.16
It is also important to consider the
potential for attrition to introduce spur-
ious differences between randomised
groups, if the degree of bias resulting
from attrition differs between groups.
This can be addressed by performing a
sensitivity analysis. In its simplest terms
this could estimate how different the
result would have to be in subjects not
seen at follow-up in order to negate the
difference between groups observed in
those who were successfully studied.
Another important consideration in
RCTs is whether the intervention itself
results in differential attrition and conse-
quent bias between groups, which would
affect the continued validity of the rando-
misation for later outcomes. This can be
easily examined and has not generally
been observed in follow-ups of nutritional
intervention trials to date.5–7 10 13 17–19
CONCLUSIONS
Long-term follow-up of RCTs and obser-
vational cohorts is an essential compo-
nent of research into nutritional
programming in humans and in other
areas of research. Loss to follow-up is
inevitable with time, even with the best
study design and conduct. The potential
effects of attrition should be explicitly
acknowledged and dealt with when fol-
low-up studies are analysed and reported,
in the context of the aims of the study. In
particular, it is important to address the
issues of bias and generalisability of
findings as far as possible and, in the case
of RCTs, to examine whether the inter-
vention has influenced attrition. The
adequacy of the sample size attained at
follow-up to detect the hypothesised
effect should also be addressed, particu-
larly when there are negative findings and
there is substantial attrition. In general,
Box 1 Summary points
c Long-term follow-up of randomised controlled trials (RCTs) and prospective
observational cohorts is an essential component of research into nutritional
programming in humans.
c Loss to follow-up is inevitable with time, even with the best study design and conduct.
c The statistical consequences of attrition – loss of power, bias and generalisability, may
vary depending on the design and aims of the study.
c The issue of attrition should be explicitly discussed in the context of each study.
c It is unnecessary and unhelpful to use fixed levels for ‘‘acceptable’’ follow-up rates, and
this practice may curtail future research in this field.
Box 2 Suggested minimum reporting requirements for addressing attrition in
long-term follow-up studies
1. Provide clear, unambiguous information on the flow of subjects through the study/
cohort at each stage. Give explicit information on the attrition rate and the attrition in
each group for a randomised trial.
2. Discuss the ability of the follow-up study to detect the hypothesised outcome effect
with the sample size attained.
3. Discuss the potential for attrition to have introduced bias. Do baseline and/or
measured variables differ in those seen and not seen? Provide baseline
characteristics for those seen and not seen at follow-up separately for each
intervention group.
4. Discuss whether attrition is likely to have affected the generalisability of the findings
to the original study population (which may or may not have been representative of
the larger population) and to the general population.
5. Provide an appropriate sensitivity analysis; describe the assumptions on which it is
based.*
*In its simplest terms this could estimate how different the result would have to be in
subjects not seen at follow-up to negate the difference between groups observed in those
who were successfully studied.
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results should be presented as estimates of
effect size with confidence limits. In all
cases, the interpretation of results should
include a discussion of the potential
effects of attrition. Suggested reporting
requirements relating to attrition are
listed in Box 2: more general and compre-
hensive reporting requirements for obser-
vational studies have been developed by
the STROBE group.20 We believe that,
providing these issues are acknowledged
and addressed, it is unreasonable and
unnecessary to use cut-offs for ‘‘accepta-
ble’’ follow-up rates, such as those pro-
posed for short-term pharmaceutical
trials. Indeed, the application of such
criteria will effectively curtail further
research into the long-term effects of
early nutrition on later health outcomes
and potentially prevent the development
of evidence-based guidelines for pregnant
women and their offspring.
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Long-term effect of repeated antenatal steroid
A single course of steroid given to women at risk of preterm delivery improves neonatal
morbidity and mortality. If delivery is more than 7 days after steroid administration, however,
perinatal mortality is increased and birth weight decreased. The effects of repeated courses of
steroid are uncertain though there is evidence that they may have a beneficial effect on the
neonatal lung but reduce birth weight. Now two follow-up studies of randomised trials in
Australia and New Zealand and in the USA have been reported (Caroline A Crowther and
colleagues. New England Journal of Medicine 2007;357:1179–89 and Ronald J Wapner and
colleagues, ibid: 1190–8; see also editorial, ibid: 1248–50).
A total of 982 women (1146 fetuses) in Australia and New Zealand and 495 (594 fetuses) in the
USA, all at risk of delivery before 32 weeks, were randomised to weekly betamethasone or
placebo>7 days after first steroid administration. The weekly dose of betamethasone was higher
in the USA (12 mg on two successive days vs 11.4 mg on one day only). The short-term
beneficial results were reported in the Lancet (Australian study) and in the American Journal of
Obstetrics and Gynecology (US study) in 2006.
Totals of 1047 and 556 children were assessed at 2–3 years of age. Neither study showed
significant differences between the betamethasone or placebo groups in rates of major
neurodevelopmental problems nor in body size or blood pressure. Attention problems were
more common among the repeated steroid group in Australia and New Zealand and there was a
statistically nonsignificant increase in cerebral palsy in the repeated steroid group (2.9% vs 0.5%,
p = 0.12) in the USA. These researchers come to different conclusions. Crowther and colleagues
suggest that clinicians ‘‘may wish to consider’’ repeat steroid administration whereas Wapner
and colleagues conclude that their findings (a possible increase in risk of cerebral palsy) ‘‘argue
against’’ this policy. Could the higher dose of betamethasone in the American study have
affected the results? Only further research will tell.
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